NICE still wants more info on RoActemra for RA patients
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has again asked Roche for more information on RoActemra (tocilizumab) before it decides whether to recommend it for treating some rheumatoid arthritis (RA) patients on the NHS.